FDA says Australia's Media Networks Sydney failed to answer drug records requests for OTC Combantrin Chocolate Squares.
What happened
FDA reviewed import records showing a shipment of Combantrin Chocolate Squares into the US on April 11, 2024, declared Media Networks Sydney as manufacturer. FDA sent an electronic request for records on May 28, 2024, and follow-ups through April 4, 2025, but says they went unanswered. FDA also contacted the firm on December 18, 2024, to announce an inspection; the firm said it had not started production in Australia and asked to reschedule, which FDA said contradicted the import records.
What FDA found
The company did not answer FDA's electronic request for records or repeated follow-up requests.
section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)FDA says refusing access to records is a prohibited act.
section 301(e) of the FD&C Act, 21 U.S.C. 331(e)FDA said the firm's statement that it had not started production in Australia conflicted with import records showing drugs made at its facility were shipped to the US.
FDA said drugs may be deemed adulterated when an owner delays, denies, limits, or refuses an inspection.
section 501(j) of the FD&C Act
What FDA wants
FDA asks the company to respond in writing within 15 working days, either with information for FDA to assess or with a request to schedule an inspection.
Who should pay attention
- US importers and distributors of Combantrin Chocolate Squares
- retailers and brands sourcing OTC drugs from Australian manufacturers
- drug companies whose FDA records requests or inspection scheduling could be delayed
This is a summary. Read the original letter on fda.gov.